FDA peptide panel includes advocates of unproven treatments backed by RFK Jr.

Conflict-of-interest narrative that presupposes regulatory capture; frames panel inclusion as problematic before presenting evidence or expert justification for selections.

This reflects internal U.S. political dynamics rather than international geopolitics. It indicates potential influence of RFK Jr.'s health policy agenda on FDA regulatory processes, affecting the balance between scientific consensus and alternative medicine advocacy within American institutional structures.

Consumers face increased risk of accessing unproven peptide treatments if regulatory oversight is compromised. This could lead to wasted spending on ineffective products, potential health risks, and erosion of trust in FDA approval processes.

Likely congressional scrutiny of FDA panel composition and conflict-of-interest policies. Potential regulatory reforms requiring stricter vetting of advisory panel members and disclosure of financial/ideological ties. May trigger investigations into RFK Jr.'s influence on health policy.